索非布韦治疗与丙型肝炎病毒感染
Sofosbuvir treatment and hepatitis C virus infection.
作者信息
Nakamura Masato, Kanda Tatsuo, Haga Yuki, Sasaki Reina, Wu Shuang, Nakamoto Shingo, Yasui Shin, Arai Makoto, Imazeki Fumio, Yokosuka Osamu
机构信息
Masato Nakamura, Tatsuo Kanda, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan.
出版信息
World J Hepatol. 2016 Jan 28;8(3):183-90. doi: 10.4254/wjh.v8.i3.183.
Abstract
Hepatitis C virus (HCV) infection is a serious problem worldwide. The use of interferon-based therapy has made HCV eradication challenging. The recent appearance of direct-acting antiviral agents (DAAs) has changed HCV therapy. Combining the use of DAAs with peginterferon and ribavirin has improved treatment efficacy. Furthermore, the combination of different orally administered DAAs has enabled interferon-free therapy with much higher efficacy and safety. In particular, sofosbuvir, a nucleotide-based NS5B inhibitor, prevents HCV RNA synthesis by acting as a "chain terminator". Treatment with sofosbuvir has attained an extremely high rate of sustained virologic response. The current review summarizes the efficacy and safety of sofosbuvir therapy.
摘要
丙型肝炎病毒（HCV）感染是一个全球性的严重问题。基于干扰素的治疗方法使得根除HCV具有挑战性。直接作用抗病毒药物（DAA）的近期出现改变了HCV治疗格局。将DAA与聚乙二醇干扰素和利巴韦林联合使用提高了治疗效果。此外，不同口服DAA的联合使用使得无需干扰素治疗成为可能，且疗效和安全性更高。特别是，基于核苷酸的NS5B抑制剂索磷布韦通过充当“链终止剂”来阻止HCV RNA合成。索磷布韦治疗已实现极高的持续病毒学应答率。本综述总结了索磷布韦治疗的疗效和安全性。
相似文献
1
Sofosbuvir treatment and hepatitis C virus infection.索非布韦治疗与丙型肝炎病毒感染
World J Hepatol. 2016 Jan 28;8(3):183-90. doi: 10.4254/wjh.v8.i3.183.
2
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .索磷布韦（索华迪°）。对丙型肝炎病毒有活性，但评估不完整。
Prescrire Int. 2015 Jan;24(156):5-10.
3
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.索磷布韦联合利巴韦林加或不加聚乙二醇干扰素-α治疗丙型肝炎病毒基因型 3 感染且有肝硬化的经治患者和丙型肝炎病毒基因型 2 感染且有肝硬化的经治患者的疗效。
Gastroenterology. 2015 Nov;149(6):1462-70. doi: 10.1053/j.gastro.2015.07.043. Epub 2015 Aug 4.
4
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.核苷酸聚合酶抑制剂索非布韦联合利巴韦林治疗丙型肝炎。
N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.
6
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.索磷布韦联合利巴韦林加或不加聚乙二醇干扰素治疗丙型肝炎病毒：来自中国 3b 期研究的结果。
J Gastroenterol Hepatol. 2018 Jun;33(6):1168-1176. doi: 10.1111/jgh.14102. Epub 2018 Mar 25.
7
Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.用于治疗伴有肝硬化的慢性丙型肝炎病毒感染的抗病毒疗法。
World J Hepatol. 2015 May 18;7(8):1133-41. doi: 10.4254/wjh.v7.i8.1133.
8
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.索磷布韦联合聚乙二醇干扰素 α-2a 和利巴韦林治疗初治慢性丙型肝炎病毒基因型 1 感染患者（ATOMIC）：一项开放标签、随机、多中心 2 期临床试验。
Lancet. 2013 Jun 15;381(9883):2100-7. doi: 10.1016/S0140-6736(13)60247-0. Epub 2013 Mar 15.
9
Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis.基于索磷布韦的抗病毒治疗为台湾失代偿期肝硬化慢性丙型肝炎患者提供了高度的治疗疗效、安全性和良好的耐受性。
J Chin Med Assoc. 2022 Feb 1;85(2):152-159. doi: 10.1097/JCMA.0000000000000653.
10
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.在从含干扰素方案向无干扰素方案转变的时代，丙型肝炎治疗从“应答导向”转向“资源导向”疗法。
J Gastroenterol Hepatol. 2017 Aug;32(8):1436-1442. doi: 10.1111/jgh.13747.
引用本文的文献
1
Sofosbuvir Polymorphs Distinguished by Linearly and Circularly Polarized Raman Microscopy.通过线性和圆偏振拉曼显微镜区分的索磷布韦多晶型物。
Anal Chem. 2024 Dec 3;96(48):18983-18993. doi: 10.1021/acs.analchem.4c03573. Epub 2024 Nov 21.
2
Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus (HCV): In silico and in vitro studies.α-山竹黄酮、胡椒碱和β-谷甾醇作为丙型肝炎抗病毒剂（HCV）：计算机模拟和体外研究。
Heliyon. 2023 Sep 15;9(9):e20141. doi: 10.1016/j.heliyon.2023.e20141. eCollection 2023 Sep.
3
Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of and Evidence.索磷布韦治疗戊型肝炎病毒感染：一项综述及证据
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003. Epub 2022 Feb 22.
4
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.烯基非环核苷膦酸酯前药的简便合成与生物评价。
Bioorg Med Chem. 2018 Jul 23;26(12):3596-3609. doi: 10.1016/j.bmc.2018.05.034. Epub 2018 May 23.
5
Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.丙型肝炎病毒（HCV）聚合酶变构抑制剂的生物物理作用模式及选择性分析
Viruses. 2017 Jun 16;9(6):151. doi: 10.3390/v9060151.
6
Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.亚洲裔美国慢性丙型肝炎和晚期肝病患者使用无干扰素直接抗病毒疗法的真实世界经验。
Medicine (Baltimore). 2017 Feb;96(6):e6128. doi: 10.1097/MD.0000000000006128.
7
Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes.尼多病毒RNA聚合酶：处理特殊RNA基因组的复杂酶类。
Virus Res. 2017 Apr 15;234:58-73. doi: 10.1016/j.virusres.2017.01.023. Epub 2017 Feb 6.
8
How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.丙型肝炎患者如何应对聚乙二醇干扰素和利巴韦林治疗的过程：一项定性研究。
BMC Health Serv Res. 2016 Jul 11;16:247. doi: 10.1186/s12913-016-1503-6.
9
Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.丙型肝炎病毒感染失代偿期肝硬化患者的无干扰素治疗
Hepatol Int. 2017 Jan;11(1):38-44. doi: 10.1007/s12072-016-9749-y. Epub 2016 Jun 9.
本文引用的文献
1
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.在日本丙型肝炎病毒患者中，达卡他韦+阿舒瑞韦与特拉匹韦+聚乙二醇干扰素/利巴韦林的随机对照比较
J Gastroenterol Hepatol. 2016 Jan;31(1):14-22. doi: 10.1111/jgh.13073.
2
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.来迪派韦和索磷布韦用于治疗合并感染HIV-1的丙型肝炎病毒患者。
N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.
3
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.达卡他韦联合索非布韦治疗 HIV-1 合并 HCV 感染。
N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21.
4
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.丙型肝炎指南：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染成人检测、管理及治疗的建议
Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4.
5
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.来迪派韦索磷布韦与利巴韦林联合治疗晚期肝病患者的 HCV 感染。
Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.
6
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.在未经治疗和先前经治的日本基因 1 型丙型肝炎患者中，使用利巴韦林联合或不联合利巴韦林的雷迪帕韦和索非布韦固定剂量复方制剂治疗 12 周：一项开放标签、随机、3 期临床试验。
Lancet Infect Dis. 2015 Jun;15(6):645-53. doi: 10.1016/S1473-3099(15)70099-X. Epub 2015 Apr 8.
7
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.索菲布韦联合利巴韦林治疗 HIV 合并丙型肝炎病毒感染患者（PHOTON-2）：一项多中心、开放性标签、非随机、3 期研究。
Lancet. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4.
8
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.丙型肝炎病毒基因3型感染患者使用达卡他韦加索磷布韦进行12周全口服治疗：ALLY-3 III期研究
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.
9
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.在2期和3期临床试验中，接受索磷布韦治疗的1-6型丙型肝炎病毒感染受试者耐药性发生频率较低。
Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28.
10
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.索磷布韦联合利巴韦林治疗日本慢性基因2型丙型肝炎病毒感染患者：一项开放标签的3期试验。
J Viral Hepat. 2014 Nov;21(11):762-8. doi: 10.1111/jvh.12312. Epub 2014 Sep 8.
Zotero 插件